Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

Learn more about:
Related Clinical Trial
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). PARP Inhibition for Gliomas (PI-4G or π4g) PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models Proteomic Characterization of Aggressive Oligodendrogliomas A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Sunitinib in Treating Patients With Recurrent Malignant Gliomas A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Pediatric Long-Term Follow-up and Rollover Study Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Social Determinants of Health in Glioblastoma Population Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Genetic Analysis of Brain Tumors Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Everolimus in Treating Patients With Recurrent Low-Grade Glioma Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Everolimus With and Without Temozolomide in Adult Low Grade Glioma Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Clinical Development of MR Spectroscopy and Imaging in Brain Cancers Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants First in Patient Study for PF-06840003 in Malignant Gliomas A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Prolonged Daily Temozolomide for Low-Grade Glioma Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Treatment Strategy for Low-grade Gliomas Neural Basis of Language Processing Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma Abemaciclib in Patients With Oligodendroglioma Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Brief Title

Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

Official Title

A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy

Brief Summary

      This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy
      (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to
      the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small
      doses on a specific timed interval, instead of delivering one large dose at one time. This
      technique may improve efficacy while reducing toxicity and improving patient quality of life.
    



Study Type

Interventional


Primary Outcome

Frequency of intolerable toxicities

Secondary Outcome

 Change in symptom burden as measured by M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)

Condition

Astrocytoma

Intervention

temporally-modulated pulsed radiotherapy (TMPRT)

Study Arms / Comparison Groups

 Arm 1: temporally-modulated pulsed radiotherapy (TMPRT)
Description:  Patients receive TMPRT daily as 10 pulses of 0.2 Gy each with a 3-minute interval between pulses (effective dose rate = 0.0667 Gy/min) to a total dose of 54 Gy at 2 Gy per day. Treatment continues for a total of 27 fractions in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Radiation

Estimated Enrollment

12

Start Date

August 31, 2022

Completion Date

August 31, 2027

Primary Completion Date

August 31, 2027

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed recurrent IDH-mutant gliomas (either astrocytoma or
             oligodendroglioma) with prior external beam radiation therapy (EBRT) to the same
             region. The recurrent tumor may be either histologically confirmed or based on
             clinical assessment. Any lesion size or any number of prior recurrences are allowed.

          -  Prior EBRT is ≥ 2 years ago.

          -  The region for reirradiation should have received at least 45 Gy from the prior EBRT
             but no more than 75 Gy. The prior EBRT could be either photon-based or proton-based.

          -  Prior SRS to the same region is permitted as long as the cumulative dose of EBRT plus
             SRS is no more than 75 Gy. The prior SRS should be completed at least 6 months ago.

          -  Life expectancy ≥ 12 months

          -  At least 18 years of age.

          -  Karnofsky performance status (KPS) of at least 70%.

          -  Females of childbearing potential (defined as a female who is non-menopausal or
             surgically sterilized) must be willing to use an acceptable method of birth control
             (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom
             with spermicide, or abstinence) for the duration of the study. Should a woman become
             pregnant or suspect she is pregnant while participating in this study, she must inform
             her treating physician immediately.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document (legally authorized representative permitted).

        Exclusion Criteria:

          -  Leptomeningeal or metastatic involvement.

          -  Use of concurrent bevacizumab or other anti-VEGF-directed therapy during TMPRT is not
             allowed. If the patient is on bevacizumab, the patient needs to discontinue
             bevacizumab for at least 4 weeks prior to the start of TMPRT and remain stable. Other
             chemotherapy, immunotherapy, or target therapy can be used concurrently or adjuvantly
             at the discretion of treating physician.

          -  Medical contraindication to MRI (e.g., unsafe foreign metallic implants, incompatible
             pacemaker, inability to lie still for long periods, severe to end-stage kidney disease
             or on hemodialysis).

          -  Pregnant.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jiayi Huang, M.D., 314-273-2931, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT05393258

Organization ID

202205105


Responsible Party

Sponsor

Study Sponsor

Washington University School of Medicine


Study Sponsor

Jiayi Huang, M.D., Principal Investigator, Washington University School of Medicine


Verification Date

June 2022